Your activity: 30 p.v.
< Back
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Sulfasalazine and 5-aminosalicylic acid (5-ASA) formulations

Sulfasalazine and 5-aminosalicylic acid (5-ASA) formulations
Medication Trade name (US or as noted) Strength of commonly available oral preparations (mg)
Oral 5-aminosalycylic acid (5-ASA) derivatives
Sulfasalazine
Non enteric-coated tablet (scored) Azulfidine, Sulfazine, Salazopyrin* 500
Suspension Salazopyrin* 250 per 5 mL*
Enteric-coated tablet (not scored) Azulfidine EC, Sulfazine EC, Salazopyrin EN-tabs* 500
Mesalamine
Delayed release enteric-coated tablet AsacolΔ◊, Asacol HD◊ 400Δ, 800
Capsule containing delayed release tablet Delzicol 400
Delayed and extended release tablet, multimatrix Lialda, Mezavant* 1200
Capsule containing delayed release enteric-coated granules Apriso 375
Controlled release capsule Pentasa§ 250, 500, 1000*
Enteric-coated delayed release granules (packet, sachet) Salofalk*, Pentasa Sachet* 500, 1000, 1500, 2000 sachet*
Olsalazine capsule Dipentum 250, 500*
Balsalazide
Capsule Colazal, Colazide* 750
Tablet Giazo¥ 1100
US: United States.
* Not available in US. Trade names shown are for products commonly available elsewhere (eg, Canada, United Kingdom, and Europe).
¶ Mesalamine is US generic name. Mesalazine is an international generic name.
Δ Asacol 400 mg tablets are no longer marketed in US. Asacol 400 mg delayed-release tablets and generic versions are available widely elsewhere.
§ According to US prescribing information, Pentasa capsules can be swallowed whole or opened and contents sprinkled over spoonful of applesauce or yogurt and swallowed immediately; capsule contents should not be crushed or chewed.
¥ US approval is limited to treatment of ulcerative colitis in male patients; failed to demonstrate efficacy in female patients.
Data courtesy of authors with additional data from: Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380:1606.
Graphic 86818 Version 14.0